PA8843701A1 - Derivados de indolina y métodos para usarlos - Google Patents

Derivados de indolina y métodos para usarlos

Info

Publication number
PA8843701A1
PA8843701A1 PA20098843701A PA8843701A PA8843701A1 PA 8843701 A1 PA8843701 A1 PA 8843701A1 PA 20098843701 A PA20098843701 A PA 20098843701A PA 8843701 A PA8843701 A PA 8843701A PA 8843701 A1 PA8843701 A1 PA 8843701A1
Authority
PA
Panama
Prior art keywords
methods
indoline derivatives
compounds
indoline
compositions
Prior art date
Application number
PA20098843701A
Other languages
English (en)
Inventor
R Schrimpf Michael
Hung Lee Chih
Li Tao
A Gfesser Gregory
H Mortell Kathleen
Faghih Ramin
L Nersesian Diana
B Sippy Kevin
H Bunnelle William
Scanio Marc
Shi Lei
Gopalakrishnan Murali
Donnelly Roberts Diana
Hu Min
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PA8843701A1 publication Critical patent/PA8843701A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry

Abstract

DERIVADOS DE INDOL Y DE INDOLINA DE FÓRMULA(I),(II),(III),(IV),(V)O(VI)DONDE A,R1,R2,R3,R4,R5,U,V,W,X,Y y Z SON COMO SE LOS DEFINE EN LA MEMORIA DESCRIPTIVA.COMPOSICIONES QUE COMPRENDEN ESTOS COMPUESTOS,MÉTODOS PARA TRATAR CONDICIONES DE ENFERMEDAD MEDIANTE EL USO DE ESTOS COMPUESTOS Y DE ESTAS COMPOSICIONES Y MÉTODOS PAR IDENTIFICAR ESTOS COMPUESTOS.
PA20098843701A 2008-09-29 2009-09-28 Derivados de indolina y métodos para usarlos PA8843701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10105408P 2008-09-29 2008-09-29
US22545209P 2009-07-14 2009-07-14

Publications (1)

Publication Number Publication Date
PA8843701A1 true PA8843701A1 (es) 2010-05-26

Family

ID=42060424

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098843701A PA8843701A1 (es) 2008-09-29 2009-09-28 Derivados de indolina y métodos para usarlos

Country Status (11)

Country Link
US (2) US9063126B2 (es)
EP (1) EP2344505A2 (es)
JP (1) JP2012504137A (es)
CN (1) CN102227431A (es)
AR (1) AR073701A1 (es)
CA (1) CA2737031A1 (es)
MX (1) MX2011003435A (es)
PA (1) PA8843701A1 (es)
TW (1) TW201018694A (es)
UY (1) UY32147A (es)
WO (1) WO2010036998A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP5586577B2 (ja) * 2008-03-24 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 架橋複素環化合物およびその使用
US9625475B2 (en) * 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
AU2009308708B2 (en) 2008-10-31 2015-11-19 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
CA2760541A1 (en) 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido[4,3-b] indoles and methods of use
US8859561B2 (en) * 2009-09-23 2014-10-14 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
US9079904B2 (en) 2009-09-23 2015-07-14 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
WO2011038164A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
WO2011084433A2 (en) * 2009-12-17 2011-07-14 Abbott Laboratories Aza-bridged ring-fused indoles and indolines
US8524703B2 (en) 2009-12-17 2013-09-03 Abbvie Inc. Bridgehead amine ring-fused indoles and indolines
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9187471B2 (en) * 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
CN103476416B (zh) 2011-02-18 2016-09-21 梅迪维新技术公司 治疗高血压的化合物和方法
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
US20140155384A1 (en) 2011-02-18 2014-06-05 Medivation Technologies, Inc. Compounds and methods of treating diabetes
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
EP2781521A4 (en) 2011-10-19 2015-03-04 Kowa Co NOVEL COMPOUND OF SPIROINDOLINE AND THERAPEUTIC AGENT CONTAINING THE SAME
WO2013085922A1 (en) * 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
JP2015509075A (ja) * 2011-12-09 2015-03-26 デメレックス， インコーポレイテッド ノルイボガインの硫酸エステル
JP6653573B2 (ja) 2012-05-22 2020-02-26 トラスティーズ・オブ・ダートマウス・カレッジ シクロアルカニル［ｂ］インドール、シクロアルカニル［ｂ］ベンゾフラン、シクロアルカニル［ｂ］ベンゾチオフェンを合成するための方法、化合物および使用の方法
JP2016508979A (ja) 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン
CN114409680B (zh) * 2018-01-19 2023-11-21 上海怡立舍生物技术有限公司 Ppar激动剂及其应用
CN113121543B (zh) * 2021-04-26 2022-03-15 重庆理工大学 一种吖庚环并[4,5-b]吲哚化合物的制备方法
CN116589726B (zh) * 2023-07-11 2023-09-22 中北大学 一种检测酪氨酸的复合膜传感器的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409628A (en) 1966-05-12 1968-11-05 Hoffmann La Roche 5-(3-pyridylethyl)pyridoindole derivatives
DE2854941A1 (de) 1978-12-20 1980-07-10 Troponwerke Gmbh & Co Kg Indolo eckige klammer auf 3.2-b eckige klammer zu chinuclidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4591983A (en) 1984-07-09 1986-05-27 Teknowledge, Inc. Hierarchical knowledge system
AU632458B2 (en) 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
US5250537A (en) 1992-03-13 1993-10-05 Scios Nova Inc. 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole,-6,7,8,9,10-hexahydro-7,11-imino-5H-cyclooct[b]indole and substituted derivatives
US5688807A (en) 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
RU2106864C1 (ru) 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
DE19615265A1 (de) 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
US5811551A (en) 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
JP4762465B2 (ja) 1999-06-15 2011-08-31 ブリストル−マイヤーズ スクイブ ファーマ カンパニー 置換複素環縮合ガンマーカルボリン
ATE504572T1 (de) 1999-09-02 2011-04-15 Shionogi & Co Derivate von aromatische heterocyclen enthaltende integraseinhibitoren
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
JP2004509893A (ja) 2000-09-20 2004-04-02 ファルマシア・アンド・アップジョン・カンパニー 置換型アゼピノ［４，５ｂ］インドリン誘導体
EP1401449B1 (en) 2001-06-05 2007-04-25 Lilly Icos LLC Tetracyclic compounds as pde5-inhibitors
JP2005526691A (ja) 2001-08-08 2005-09-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 治療剤１Ｈ−ピリド［４，３−ｂ］インドール
WO2004063156A1 (en) 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
US20050143371A1 (en) * 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
US7309699B2 (en) 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
KR20060129077A (ko) 2004-03-09 2006-12-14 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 만성 염증 질환을 치료하기 위한 사이토킨 생성억제제로서의3-'4-헤테로사이클릴-1,2,3-트리아졸-1-일-ｎ-아릴-벤즈아미드
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
BRPI0614485A2 (pt) 2005-07-28 2011-03-29 Bristol-Myers Squibb Company tetrahidro-1h-pirido [4, 3, b] indóis substituìdos como agonistas e antagonistas receptores de serotonina
EP1747779A1 (en) 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
ATE489087T1 (de) 2006-10-24 2010-12-15 Congenia S R L Phenyl-substituierte maleimide als medikamente zur hemmung von degenerativen gewebeschäden durch hemmung von mpt
JP2010507672A (ja) 2006-10-27 2010-03-11 メディベイション ニューロロジー， インコーポレイテッド アルツハイマー病を治療するための方法および組み合わせ治療
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
FR2911142A1 (fr) * 2007-01-05 2008-07-11 Servier Lab Nouveaux derives aminopyrrolo[1,2-a]indole et aminopyridazino[1,6-a]indole,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW200848417A (en) * 2007-02-22 2008-12-16 Organon Nv Indole derivatives
MX2009009113A (es) * 2007-03-06 2009-09-04 Astrazeneca Ab Nuevos indoles 2-heteroaril sustituidos 695.
KR102065319B1 (ko) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
AU2008269513B2 (en) 2007-06-26 2011-06-16 Astrazeneca Ab 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors
CA2700160A1 (en) 2007-09-20 2009-03-26 D2E, Llc Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
AU2009228398B2 (en) 2008-03-24 2014-07-03 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
JP5586577B2 (ja) 2008-03-24 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 架橋複素環化合物およびその使用
WO2011038164A1 (en) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
US8524703B2 (en) 2009-12-17 2013-09-03 Abbvie Inc. Bridgehead amine ring-fused indoles and indolines

Also Published As

Publication number Publication date
EP2344505A2 (en) 2011-07-20
US9063126B2 (en) 2015-06-23
TW201018694A (en) 2010-05-16
US20100087471A1 (en) 2010-04-08
JP2012504137A (ja) 2012-02-16
WO2010036998A3 (en) 2011-03-03
MX2011003435A (es) 2011-05-02
WO2010036998A2 (en) 2010-04-01
CA2737031A1 (en) 2010-04-01
UY32147A (es) 2010-04-30
US20150353550A1 (en) 2015-12-10
AR073701A1 (es) 2010-11-24
CN102227431A (zh) 2011-10-26

Similar Documents

Publication Publication Date Title
PA8843701A1 (es) Derivados de indolina y métodos para usarlos
CL2011002825A1 (es) Compuestos derivados de bencimidazol heteroarilo sustituido; composición farmacéutica que los comprende; y su uso en el tratamiento de la hepatitis c.
SV2011003853A (es) Compuestos organicos
UY36907A (es) Nuevas carboxamidas de acción microbiocida
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
DOP2010000375A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
SV2006002098A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
CU20110078A7 (es) Compuestos de carbazol
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
PA8854001A1 (es) Compuestos novedosos como ligandos de receptores de canabinoides
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
GT200900026A (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
PA8855001A1 (es) Monocarbamas
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
ECSP11011217A (es) Microbiocidas nuevos.